查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401785

血紅蛋白病市場，按類型、治療、配銷通路、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Hemoglobinopathies Market, By Type, By Therapy, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 298 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022 年血紅素病市場規模為 84.28 億美元，2023 年至 2030 年複合CAGR為 12.5%。

血紅素病市場-市場動態

發展中國家和低收入國家血紅素病患病率不斷上升，推動了市場成長

血紅蛋白疾病，包括鐮狀細胞疾病和地中海貧血，是可以預防的遺傳性疾病。嚴重時，它們與慢性、危及生命和損害生命的疾病有關，具有重大健康風險，可能導致死亡或殘疾。不幸的是，由於缺乏知識、全面的計劃和有組織的預防措施，全世界很大一部分兒童出生時就患有這些疾病。根據華大基因2023年全球基因組報告，全球有5.2%的人患有血紅蛋白異常，這導致每年有30萬至40萬嬰兒出生時患有嚴重的血紅蛋白疾病。此外，每 10,000 名活產兒中就有 4.4 人患有地中海貧血，這是一種遺傳性血紅蛋白病，在地中海沿岸地區、非洲、中東、東南亞和中國南部最為常見。大約 80% 的地中海貧血病例發生在低收入和中等收入國家，這些國家的患者的生活品質更有可能因獲得醫療服務的機會不平等而受到​​威脅。控制地中海貧血的計畫必須包括遺傳諮詢、篩檢、公眾意識和產前診斷。考慮到問題的嚴重性和管理成本的影響，需要立即採取適當的控制措施。

血紅蛋白病市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2023-2030 年）每年將以 12.5% 左右的CAGR成長

根據類型細分，鐮狀細胞疾病細分市場預計將在預測期內主導市場

從地區來看，預計北美在預測期內將主導市場

血紅素病市場細分分析：

全球血紅蛋白病市場根據類型、治療、配銷通路和區域進行細分。

根據類型，全球市場分為鐮狀細胞疾病、地中海貧血等。鐮狀細胞疾病預計將在預測期內主導市場。鐮狀細胞疾病診斷市場最近出現了一些顯著的發展。新型診斷技術的創造和採用就是這樣的趨勢之一。現代基因檢測技術，包括次世代定序和分子診斷，使得更準確、更有效地識別鐮狀細胞疾病及其變異成為可能。快速診斷套件和即時檢測 (POCT) 設備也已開發出來，使各種醫療保健環境中的篩檢變得快速、輕鬆。例如，Molbio Diagnostics 和 ShanMukha Innovations 於 2023 年 5 月合作，創建、開發和銷售價格實惠的床邊診斷工具，用於診斷與血紅蛋白疾病相關的疾病。

根據治療方法，全球血紅素病產業分為ACE抑制劑、單株抗體藥物、羥基脲等。

根據配銷通路，市場分為線上提供者、醫院藥房、藥局和零售藥房。

血紅素病市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。預計北美將在預測期內主導市場，因為醫療保健設施越來越好，人們對血紅蛋白病的認知也越來越高。不同的團體進行不同的活動來提高意識。例如，美國國家組織 SCDAA 透過提高意識和提供支持來倡導鐮狀細胞疾病患者及其家人的利益。為了提高人們對這種疾病的認知並改善他們的生活，他們安排活動、提供資源並提供指導材料。由於政府機構和研究機構推出了多項支持血紅蛋白病新療法開發的計劃，預計該地區的市場將會成長。

血紅素病市場-競爭格局：

為了增加市場佔有率，企業領導者正在採取多種措施，包括建立夥伴關係、協作、併購以及密集研發。市場上的主要參與者包括諾華公司、新基公司、藍鳥生物公司、Emmaus Life Sciences Inc.、輝瑞公司、Sangamo Therapeutics, Inc.、Prolong Pharmaceuticals, LLC、Global Blood Therapeutics, Inc.、Gamida Cell 和Bioverativ公司

最近的發展：

2023年8月，美國FDA解除了FTX-6058新藥臨床試驗（IND）申請的臨床擱置，可用於治療鐮狀細胞疾病（SCD）。 Fulcrum Therapeutics, Inc. 是一家臨床階段的生物製藥公司，優先考慮改善患有基因罕見疾病的患者的生活。

目錄

第1章：血紅蛋白病市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按類型分類的血紅蛋白病市場片段
    • 血紅素病治療市場片段
    • 按配銷通路分類的血紅蛋白病市場片段
    • 按國家/地區分類的血紅素病市場片段
    • 按地區分類的血紅素病市場片段
  • 競爭洞察

第 3 章：血紅蛋白疾病主要市場趨勢

  • 血紅素病市場促進因素
    • 市場促進因素的影響分析
  • 血紅素病市場限制
    • 市場限制影響分析
  • 血紅素病市場機會
  • 血紅素病市場未來趨勢

第 4 章：血紅蛋白病產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：血紅素病市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：血紅素病市場格局

  • 2022 年血紅素病市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：血紅蛋白疾病市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 鐮形血球貧血症
    • 地中海型貧血
    • 其他

第 8 章：血紅蛋白疾病市場 - 按治療

  • 概述
    • 按療法分類的細分市場佔有率分析
    • ACE抑制劑
    • 單株抗體藥物
    • 羥基脲
    • 其他

第 9 章：血紅蛋白病市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 線上提供者
    • 醫院藥房
    • 藥局
    • 零售藥房

第 10 章：血紅蛋白疾病市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美血紅素病主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模和預測（按治療）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲血紅素病主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按治療）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區血紅素病主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（按治療）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲血紅蛋白病主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按療法）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲血紅蛋白病主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模和預測（按療法）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 血紅素病產業

  • 競爭儀表板
  • 公司簡介
    • Novartis AG
    • Celgene Corporation
    • bluebird bio, Inc.
    • Emmaus Life Sciences Inc.
    • Pfizer, Inc.
    • Sangamo Therapeutics, Inc.
    • Prolong Pharmaceuticals, LLC
    • Global Blood Therapeutics, Inc.
    • Gamida Cell
    • Bioverativ Inc.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1986

REPORT HIGHLIGHT

Hemoglobinopathies Market size was valued at USD 8,428 Million in 2022, expanding at a CAGR of 12.5% from 2023 to 2030.

Hemoglobinopathy diagnosis and treatment are becoming more and more common due to the growing demand for newborn screening programs and the diagnosis of prenatal hemoglobin abnormalities. This is particularly critical in poorer countries where screening and awareness initiatives are only getting underway. Additionally, it is anticipated that growing patient and healthcare professional awareness of the need for early diagnosis and treatment will propel market revenue growth. This is particularly true in the case of sickle cell anemia when early detection and treatment can significantly improve patient outcomes and reduce healthcare costs. However, a significant factor that can limit market revenue development is the high cost of treatment, particularly for gene therapy and stem cell transplants. Moreover, severe legislative limitations, and a lack of access to healthcare in developing countries, especially for those in need of specialized treatment, are increasing the prevalence of hemoglobinopathies worldwide.

Hemoglobinopathies Market- Market Dynamics

Increasing prevalence of hemoglobinopathies in developing and low-income countries boosting the market growth

Haemoglobinopathies, including sickle cell disease and Thalassemia, are hereditary conditions that can be prevented. In their severe forms, they are linked to chronic, life-threatening, and life-impairing diseases with substantial health risks that can result in death or disability. Unfortunately, due to a lack of knowledge, comprehensive programs, and organized preventative measures, a significant percentage of children worldwide are born with and suffer from these conditions. According to BGI Genomics Global 2023, 5.2% of people worldwide have hemoglobin abnormalities, which causes 300,000 to 400,000 babies to be born with severe hemoglobinopathies every year. In addition, 4.4 out of every 10,000 live births is affected with thalassemia, a hereditary hemoglobinopathy that is most common in Mediterranean coastal regions, Africa, the Middle East, Southeast Asia, and southern China. Roughly 80% of cases of thalassemia take place in low- and middle-income nations, where patients' quality of life is more likely to be in danger due to unequal access to medical care. Programs to control thalassemia must include genetic counselling, screening, public awareness, and prenatal diagnosis. Considering the magnitude of the problem and the cost implications of management, suitable control measures need to be undertaken immediately.

Hemoglobinopathies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2023-2030)

Based on type segmentation, the Sickle Cell Disease segment is expected to dominate the market over the forecast period

Based on region, North America is expected to dominate the market during the forecast period

Hemoglobinopathies Market- Segmentation Analysis:

The Global Hemoglobinopathies Market is segmented based on Type, Therapy, Distribution Channel, and Region.

Based on the type, the global market is categorized into Sickle Cell Disease, Thalassemia and Others. The Sickle Cell Disease segment is expected to dominate the market over the forecast period. The market for sickle cell disease diagnostics has seen several notable developments recently. The creation and uptake of novel diagnostic technology is one such trend. Modern genetic testing techniques, including next-generation sequencing and molecular diagnostics, have made it possible to identify sickle cell disease and its variations more precisely and effectively. Rapid diagnostic kits and point-of-care testing (POCT) equipment have also been developed, making screening quick and easy in a variety of healthcare settings. For instance, Molbio Diagnostics and ShanMukha Innovations partnered in May 2023 to create, develop, and market affordable point-of-care diagnostic tools for the diagnosis of disorders associated with hemoglobinopathy.

Based on the therapy, the global hemoglobinopathies industry is divided into ACE inhibitors, Monoclonal Antibody Medication, Hydroxyurea and Others.

Based on the distribution channel, the market is bifurcated into Online Providers, Hospital Pharmacy, Drug Stores and Retail Pharmacy.

Hemoglobinopathies Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period because healthcare facilities are getting better and individuals are becoming more aware of hemoglobinopathies. Different groups run different activities to raise awareness. For instance, the United States national group SCDAA advocates for people with sickle cell disease and their families by raising awareness and providing support. To foster greater awareness and enhance the lives of individuals who suffer from the disease, they arrange events, offer resources, and give instructional materials. The region's market is expected to rise as a result of several programs launched by government agencies and research institutions to support the development of new treatments for hemoglobinopathies.

Hemoglobinopathies Market- Competitive Landscape:

To increase their market share, business leaders are launching several efforts, including partnerships, collaborations, mergers and acquisitions, and intensive R&D. The key players operating in the market are Novartis AG, Celgene Corporation, bluebird bio, Inc., Emmaus Life Sciences Inc., Pfizer, Inc., Sangamo Therapeutics, Inc., Prolong Pharmaceuticals, LLC, Global Blood Therapeutics, Inc., Gamida Cell and Bioverativ Inc.

Recent Developments:

In August 2023, the FDA in the United States released the clinical hold on the Investigational New Drug (IND) application for FTX-6058, which could be used to treat sickle-cell disease (SCD). Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that prioritizes improving the lives of patients with genetically defined rare diseases.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEMOGLOBINOPATHIES MARKET KEY PLAYERS

  • Novartis AG
  • Celgene Corporation
  • bluebird bio, Inc.
  • Emmaus Life Sciences Inc.
  • Pfizer, Inc.
  • Sangamo Therapeutics, Inc.
  • Prolong Pharmaceuticals, LLC
  • Global Blood Therapeutics, Inc.
  • Gamida Cell
  • Bioverativ Inc.

GLOBAL HEMOGLOBINOPATHIES MARKET, BY TYPE

  • Sickle Cell Disease
  • Thalassemia
  • Others

GLOBAL HEMOGLOBINOPATHIES MARKET, BY THERAPY

  • ACE inhibitors
  • Monoclonal Antibody Medication
  • Hydroxyurea
  • Others

GLOBAL HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL

  • Online Providers
  • Hospital Pharmacy
  • Drug Stores
  • Retail Pharmacy

GLOBAL HEMOGLOBINOPATHIES MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hemoglobinopathies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hemoglobinopathies Market Snippet by Type
    • 2.1.2. Hemoglobinopathies Market Snippet by Therapy
    • 2.1.3. Hemoglobinopathies Market Snippet by Distribution Channel
    • 2.1.4. Hemoglobinopathies Market Snippet by Country
    • 2.1.5. Hemoglobinopathies Market Snippet by Region
  • 2.2. Competitive Insights

3. Hemoglobinopathies Key Market Trends

  • 3.1. Hemoglobinopathies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hemoglobinopathies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hemoglobinopathies Market Opportunities
  • 3.4. Hemoglobinopathies Market Future Trends

4. Hemoglobinopathies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hemoglobinopathies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hemoglobinopathies Market Landscape

  • 6.1. Hemoglobinopathies Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hemoglobinopathies Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Sickle Cell Disease
    • 7.1.3. Thalassemia
    • 7.1.4. Others

8. Hemoglobinopathies Market - By Therapy

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy, 2022 & 2030 (%)
    • 8.1.2. ACE inhibitors
    • 8.1.3. Monoclonal Antibody Medication
    • 8.1.4. Hydroxyurea
    • 8.1.5. Others

9. Hemoglobinopathies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Online Providers
    • 9.1.3. Hospital Pharmacy
    • 9.1.4. Drug Stores
    • 9.1.5. Retail Pharmacy

10. Hemoglobinopathies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Hemoglobinopathies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Hemoglobinopathies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Hemoglobinopathies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Hemoglobinopathies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Hemoglobinopathies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Hemoglobinopathies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. Celgene Corporation
    • 11.2.3. bluebird bio, Inc.
    • 11.2.4. Emmaus Life Sciences Inc.
    • 11.2.5. Pfizer, Inc.
    • 11.2.6. Sangamo Therapeutics, Inc.
    • 11.2.7. Prolong Pharmaceuticals, LLC
    • 11.2.8. Global Blood Therapeutics, Inc.
    • 11.2.9. Gamida Cell
    • 11.2.10. Bioverativ Inc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Hemoglobinopathies Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Hemoglobinopathies Market, by Type 2018-2030 (USD Million)
  • TABLE Hemoglobinopathies Market: Therapy Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Therapy
  • TABLE Global Hemoglobinopathies Market, by Therapy 2018-2030 (USD Million)
  • TABLE Hemoglobinopathies Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Hemoglobinopathies Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Hemoglobinopathies Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Hemoglobinopathies Market, by Region 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)